Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms

Pathobiology

Volumn 79, Issue 1, 2012, Pages 45-53

  Chang, Mee Soo ^a,b   Byeon, Sun Ju ^a   Yoon, Sun Och ^a   Kim, Baek Hui ^a   Lee, Hye Seung ^a,b   Kang, Gyeong Hoon ^a   Kim, Woo Ho ^a   Park, Kyu Joo ^c  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Appendiceal mucinous neoplasm; ERK; Leptin; mTOR; MUC2; MUC5AC; STAT3

Indexed keywords

LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 2; MUCIN 5AC; STAT3 PROTEIN;

ADENOMA; ADOLESCENT; ADULT; AGED; APPENDICEAL MUCINOUS NEOPLASM; APPENDIX TUMOR; ARTICLE; CARCINOGENESIS; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APPENDICEAL NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEPTIN; MALE; MIDDLE AGED; MUCIN 5AC; MUCIN-2; MUCINS; PSEUDOMYXOMA PERITONEI; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84862909317     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000332739     Document Type: Article

References (28)

1. Collins DC: 71,000 human appendix speci-mens, a final report summarizing forty years' study. Am J Proctol 1963; 4:265-281.
2. Carr NJ, McCarthy WF, Sobin LH: Epithe-lial noncarcinoid tumours and tumour-like lesions of the appendix. A clinicopathologi-cal study of 184 patients with a multivariate analysis of prognostic factors. Cancer 1995; 75: 757-768.
3. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH: Appendiceal mucinous neoplasms: a clinicopathological analysis of 107 cases. Am J Surg Pathol 2003; 27:1089-1103. (Pubitemid 36909530)
4. Pai RK, Longacre TA: Appendiceal muci-nous tumours and pseudomyxoma perito-nei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol 2005; 12:291-311. (Pubitemid 44357148)
5. Carr NJ, Sobin LH: Adenocarcinoma of the appendix; in Bosman FT, Carneiro F, Hru-ban RH, Theise ND (eds): World Health Or-ganization classification of the digestive sys-tem, ed 4. Lyon, IARC Press, 2010, pp 119-125.
6. Yoon SO, Kim BH, Lee HS, Kang GH, Kim WH, Kim YA, Kim JE, Chang MS: Differen-tial protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive fac-tors. Mod Pathol 2009; 22:1102-1112.
7. Young RH: Pseudomyxoma peritonei and se-lected other aspects of the spread of appendi-ceal neoplasms. Semin Diagn Pathol 2004; 21:134-150. (Pubitemid 40247215)
8. O'Connell JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH: Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002; 161:551-564. (Pubitemid 36142164)
9. Misdraji J: Appendiceal mucinous neo-plasms: controversial issues. Arch Pathol Lab Med 2010; 134: 864-870.
10. Semino-Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, Dubois A: Pseudo-myxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expres-sion in disseminated peritoneal adenomu-cinosis and peritoneal mucinous carcino-matosis. Ann Surg Oncol 2008; 15: 1414-1423.
11. Plaisancié P, Ducroc R, El Homsi M, Tsocas A, Guilmeau S, Zoghbi S, Thibaudeau O, Bado A: Luminal leptin activates mucin-se-creting goblet cells in the large bowel. Am J Physiol Gastrointest Liver Physiol 2006; 290:G805-G812.
12. El Homsi M, Ducroc R, Claustre J, Jourdan G, Gertler A, Estienne M, Bado A, Scoazec JY, Plaisancié P: Leptin modulates the ex-pression of secreted and membrane-associ-ated mucins in colonic epithelial cells by tar-geting PKC, PI3K, and MAPK pathways. Am J Physiol Gastrointest Liver Physiol 2007; 293:G365-G373. (Pubitemid 47105166)
13. Pelleymounter MA: Cullen MJ, Baker MB, et al: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-543.
14. Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, Zhao L: Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 2009; 100: 389-395.
15. Uddin S, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Al-homoud S, Al-Dayel F, Ahmed M, Al-Kuraya KS: Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009; 30:1832-1840.
16. Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, Guidi M, Terrasi M, Cetto GL, Surmacz E: Leptin and its receptor are overexpressed in brain tumours and cor-relate with the degree of malignancy. Brain Pathol 2010; 20:481-489.
17. Hursting SD, Berger NA: Energy balance, host-related factors, and cancer progression. J Clin Oncol 2010; 28:4058-4065.
18. Sweeney G: Leptin signalling. Cell Signal 2002; 14:655-663. (Pubitemid 34518619)
19. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant acti-vation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of he-patocellular carcinoma cells. Cancer Res 2007; 67:2497-2507. (Pubitemid 46548934)
20. Kim HS: Leptin and leptin receptor expres-sion in breast cancer. Cancer Res Treat 2009; 41:155-163.
21. Saxena NK, Vertino PM, Anania FA, Shar-ma D: Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activa-tion of Stat3. J Biol Chem 2007; 282: 13316-13325. (Pubitemid 47100545)
22. Hammond ME, Hayes DF, Dowsett M, All-red DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immuno-histochemical testing of estrogen and pro-gesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
23. Cappuzzo F, Hirsch FR, Rossi E, Trisolini R Paioli D, Magrini E, Finocchiaro G, Barto-lini S, Cancellieri A, Hirsch FR, Crino L, Va-rella-Garcia M: Epidermal growth factor re-ceptor gene and protein and gefitinib sensi-tivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-655. (Pubitemid 40812628)
24. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, Mc-Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Whee-ler TM, Hayes DF; American Society of Clinical Oncology/College of American Pa-thologists: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131: 18-43. (Pubitemid 46174133)
25. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216-5223.
26. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M: Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrange-ments potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16:5581-5590.
27. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E, Nadel J, Basbaum C: Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1998; 1406:251-259. (Pubitemid 28269307)
28. Easton JB, Houghton PJ: mTOR and cancer therapy. Oncogene 2006; 25:6436-6446. (Pubitemid 44582287)